[ Inside the business ]

COO stock analysis

COO · Cooper Companies, Inc.

Ophthalmic goods. Growing 1%. Keeps 13¢ of every dollar.

Watch: a leadership change, growth that has stopped speeding up.

The future, in 7 questions

Priced in: 1.1× sales in 5 yrs. Evidence: sales +1% · 13¢ profit/$1 · Software supply-chain security rising.

01 What's priced in?1.1× sales in 5 yrs
Sales now$4.2B
Needed in 5 yrs$4.5B
02 Is the wave rising?Software supply-chain security · 2.6×
'20'21'22'23'24'2513
#4 of 20 mentioning it
03 Will customers keep buying?Sales +1%, slowing
No customer over 10%
Prepaid $130MSales +1%, slowing
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Keeps 13¢ per $1
'21'22'23'24'2513¢
Before running costs: 65% → 66%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares +0.2%/yrDebt $3.2B
07 What could break it?2 to watch
  • Growth peaked
  • Moves strongly with the S&P 500

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth peaked.

Sales growth +6%, +8%, then +1% vs. a year ago. A leadership change was filed on Oct 27.

What could go wrong

Red flags.

It has moved 0.8× the market. In the 2008 crisis it fell 47% while the market fell 51%. Debt is heavy. 1 red flag in its filings.

Speculative check

Self-funding.

Passes every condition: profitable, cash-generating and financially sound.

What they sell

Not broken out.

The filings don't split revenue by product in structured data.

Where each dollar goes

13¢ profit.

34¢ to make what it sells, 53¢ on research and overhead, 13¢ left over. Revenue $4.2B in the last 12 months.

Its market

1.3× the economy.

The government expects its industry, medical equipment and supplies manufacturing, to grow 2.5% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Maturity.

It earns cash, still invests, and pays back more than it borrows.

Earnings quality

Clean.

Its numbers don't resemble those of past manipulators. Cash covers 181¢ of each $1 of profit.

Competitive advantage

2 of 10 years.

Returns beat its 7.5% cost of capital in 2 of the last 10 years. Gross margin went from 60% to 66%.

Future bets

4% on research.

$170M a year on R&D. $355M on equipment and buildings.

All figures from Cooper Companies, Inc.'s SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.